	US 12,187,702 B2
	Sulfonamideurea compounds
Matthew Cooper, Cambridge (GB); David Miller, Cambridge (GB); Angus MacLeod, Cambridge (GB); Jonathan Shannon, Nottingham (GB); Jokin Carrillo Arregui, Nottingham (GB); Jimmy Van Wiltenburg, Groningen (NL); and Jochem Theodoor Van Herpt, Groningen (NL)
Assigned to INFLAZOME LIMITED, Dublin (IE)
Appl. No. 17/267,800
Filed by Inflazome Limited, Dublin (IE)
PCT Filed Aug. 12, 2019, PCT No. PCT/EP2019/071628 § 371(c)(1), (2) Date Feb. 10, 2021, PCT Pub. No. WO2020/035464, PCT Pub. Date Feb. 20, 2020.
Claims priority of application No. 1813280 (GB), filed on Aug. 15, 2018; and application No. 1902327 (GB), filed on Feb. 20, 2019.
Prior Publication US 2022/0194923 A1, Jun. 23, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/12 (2006.01); C07C 311/30 (2006.01); C07D 205/04 (2006.01); C07D 207/48 (2006.01); C07D 243/08 (2006.01); C07D 295/26 (2006.01); C07D 487/04 (2006.01); C07D 487/08 (2006.01); C07D 487/10 (2006.01)

CPC C07D 401/12 (2013.01) [C07C 311/30 (2013.01); C07D 205/04 (2013.01); C07D 207/48 (2013.01); C07D 243/08 (2013.01); C07D 295/26 (2013.01); C07D 487/04 (2013.01); C07D 487/08 (2013.01); C07D 487/10 (2013.01)]

8 Claims

1. A compound of formula (ID):

or a pharmaceutically acceptable salt or solvate thereof, wherein:

R²⁰is selected from a bond, —CH₂— or —CH₂CH₂—;

R²¹is a 4- to 6-membered saturated heterocyclic group comprising one or two ring nitrogen atoms, wherein the heterocyclic group may optionally be substituted with one or two C₁-C₄alkyl groups;

R²³is selected from hydrogen or C₁-C₄alkyl;

and

R²is a fused aryl or a fused heteroaryl group, wherein a first cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring is fused to the aryl or heteroaryl group across the α,β positions and a second cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring is fused to the aryl or heteroaryl group across the α′,β′ positions, and wherein R²may optionally be further substituted.